Queen's gambit: response-adapted win in CAYA with cHL

Blood. 2023 Apr 27;141(17):2037-2038. doi: 10.1182/blood.2022019339.
No abstract available

Publication types

  • Editorial
  • Comment

MeSH terms

  • Adolescent
  • Bendamustine Hydrochloride
  • Brentuximab Vedotin
  • Child
  • Hodgkin Disease*
  • Humans
  • Nivolumab*
  • Young Adult

Substances

  • Brentuximab Vedotin
  • Bendamustine Hydrochloride
  • Nivolumab